Moomoo AI 已提取核心信息
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
2024年2月15日，临床阶段的癌症免疫疗法公司Compugen有限公司宣布任命医学博士米歇尔·马勒为新任首席医学官，自2024年3月1日起生效。马勒博士于2023年10月加入Compugen担任临床开发副总裁，他将接替即将离开公司寻求其他机会的医学博士亨利·阿德沃耶。马勒博士曾在包括1 E therapeutics Ltd.和Aummune Therapeutics Ltd在内的多家生物技术和制药公司任职，积累了丰富的经验。她在准备与吉利德科学合作进行的 COM503 1期研究中发挥了重要作用，并在正在进行的三联研究中发挥了关键作用。Compugen首席执行官阿纳特·科恩-达亚格博士对阿德沃伊博士为公司过渡到临床阶段以及推进其临床和监管战略所做的贡献表示感谢。Compugen以其计算靶标的发现而闻名，正在开发一系列癌症免疫疗法，包括 COM701 和 COM902，并与阿斯利康合作开发了名为rilvegostomig的第三阶段项目。
2024年2月15日，临床阶段的癌症免疫疗法公司Compugen有限公司宣布任命医学博士米歇尔·马勒为新任首席医学官，自2024年3月1日起生效。马勒博士于2023年10月加入Compugen担任临床开发副总裁，他将接替即将离开公司寻求其他机会的医学博士亨利·阿德沃耶。马勒博士曾在包括1 E therapeutics Ltd.和Aummune Therapeutics Ltd在内的多家生物技术和制药公司任职，积累了丰富的经验。她在准备与吉利德科学合作进行的 COM503 1期研究中发挥了重要作用，并在正在进行的三联研究中发挥了关键作用。Compugen首席执行官阿纳特·科恩-达亚格博士对阿德沃伊博士为公司过渡到临床阶段以及推进其临床和监管战略所做的贡献表示感谢。Compugen以其计算靶标的发现而闻名，正在开发一系列癌症免疫疗法，包括 COM701 和 COM902，并与阿斯利康合作开发了名为rilvegostomig的第三阶段项目。
有用
没用